News & Events - Page 8 of 21 - Bay City Capital

Filters

Portfolio News

July 22, 2016

Madrigal Pharmaceuticals Completes Merger with Synta

Uncategorized

July 12, 2016

Interleukin Genetics To Offer Inflammation Management Program To Amway Employees

Bay City Capital News

June 20, 2016

David Beier OpEd in Medium Discusses the Impact of Technology on the Economy

Disruption or Displacement? Weighing the Benefits and Costs of Artificial Intelligence, Robots and the Gig Economy

Portfolio News

June 13, 2016

Nevro Announces Full Exercise of Over-Allotment Option and Closing of Public Offering of $172.5 M Convertible Senior Notes

Portfolio News

June 13, 2016

Sunesis Pharmaceuticals Announces Positive Results from Trial in Frontline Elderly AML and MDS

Portfolio News

June 9, 2016

Omicia Raises $23 Million in Series B Funding

Portfolio News

June 7, 2016

Dermira Announces Proposed Public Offering of Common Stock

Portfolio News

June 6, 2016

Nevro Announces Proposed Public Offering of $125 Million Convertible Senior Notes

Portfolio News

May 19, 2016

Merus Announces Pricing of Initial Public Offering

Portfolio News

May 10, 2016

Dermira Announces Positive Topline Phase 2b Clinical Trial Results for DRM01

Portfolio News

May 6, 2016

Epizyme Appoints Matthew Ros as Chief Operating Officer

Portfolio News

May 5, 2016

Epizyme Announces FDA Acceptance of IND Application for Tazemetostat in Mesothelioma

Portfolio News

May 3, 2016

Merus Announces First Patient Dosed in Phase 1/2 Trial Evaluating MCLA-117 in AML Patients

Portfolio News

April 26, 2016

Interleukin Genetics Receives Notice of Allowance for US Patent for PerioPredict Genetic Risk Test

Portfolio News

April 21, 2016

Interleuken’s PerioPredict Genetic Risk Test Incorporated into Freedom Dental Plan